A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED® lamp

British Journal of Dermatology

Volumn 175, Issue 4, 2016, Pages 696-705

  Reinhold, U ^a   Dirschka, T ^b,c   Ostendorf, R ^d   Aschoff, R ^e   Berking, C ^f   Philipp Dormston, W G ^g   Hahn, S ^h   Lau, K ^h   Jager A ⁱ   Schmitz, B ⁱ   Lubbert H ⁱ   Szeimies, R M ^j  

^a Medical Center Bonn Friedensplatz   (Germany)

^b Urology private practice   (Germany)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

^d Private Practice   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h ACCOVION GMBH   (Germany)

ⁱ Biofrontera Pharmaceuticals GmbH   (Germany)

^j Department of Dermatology and Allergology   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; PLACEBO;

ACTINIC KERATOSIS; ADULT; AGED; APPLICATION SITE PAIN; ARTICLE; CLEARANCE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; ILLUMINATION; LOCAL SKIN REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCICEPTION; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PHOTODYNAMIC THERAPY DEVICE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; SKIN SURFACE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84990249183     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14498     Document Type: Article

References (22)

1. Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol 1998; 139:1033–9.
2. Röwert-Huber J, Patel MJ, Forschner T et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156(Suppl. 3):8–12.
3. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma (“actinic keratosis”). J Am Acad Dermatol 2000; 42(1 Pt 2):11–17.
4. Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 2007; 33:1099–101.
5. Babilas P, Karrer S, Sidoroff A et al. Photodynamic therapy in dermatology–an update. Photodermatol Photoimmunol Photomed 2005; 21:142–9.
6. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42(1 Pt 2):23–4.
7. Babilas P, Landthaler M. Szeimies RM [Actinic keratoses]. Hautarzt 2003; 54:551–60. (in German).
8. Szeimies RM, Torezan L, Niwa A et al. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 2012; 167:150–9.
9. Fernandez-Figueras MT, Carrato C, Saenz X et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 2015; 29:991–7.
10. Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents. Cutis 2012; 89:241–50.
11. Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 2: commonly used field-directed and lesion-directed therapies. Cutis 2012; 89:294–301.
12. Christensen E, Warloe T, Kroon S et al. Guidelines for practical use of MAL-PDT in non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2010; 24:505–12.
13. Vegter S, Tolley K. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS ONE 2014; 9:e96829.
14. Braathen LR, Szeimies RM, Basset-Seguin N et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007; 56:125–43.
15. Dirschka T, Radny P, Dominicus R et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol 2013; 168:825–36.
16. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol, B 1990; 6:143–8.
17. Maisch T, Santarelli F, Schreml S et al. Fluorescence induction of protoporphyrin IX by a new 5-aminolevulinic acid nanoemulsion used for photodynamic therapy in a full-thickness ex vivo skin model. Exp Dermatol 2010; 19:e302–5.
18. Szeimies RM, Radny P, Sebastian M et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol 2010; 163:386–94.
19. Dirschka T, Radny P, Dominicus R et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 2012; 166:137–46.
20. Neittaanmaki-Perttu N, Karppinen TT, Gronroos M et al. Daylight photodynamic therapy for actinic keratoses: a randomized double-blinded non-sponsored prospective study comparing BF-200 aminolevulinic acid with methyl-5-aminolaevulinate. Br J Dermatol 2014; 171:1172–80.
21. Moan J, Iani V, Ma LW. Choice of the proper wavelength for photochemotherapy. Prog SPIE 1996; 2625:544–9.
22. Ya-Xian Z, Suetake T, Tagami H. Number of cell layers of the stratum corneum in normal skin - relationship to the anatomical location on the body, age, sex and physical parameters. Arch Dermatol Res 1999; 291:555–9.